CER 128: Oral Mechanical Bowel Preparation for Colorectal Surgery

Total Page:16

File Type:pdf, Size:1020Kb

CER 128: Oral Mechanical Bowel Preparation for Colorectal Surgery Comparative Effectiveness Review Number 128 Oral Mechanical Bowel Preparation for Colorectal Surgery Comparative Effectiveness Review Number 128 Oral Mechanical Bowel Preparation for Colorectal Surgery Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-2012-00012-I Prepared by: Brown University Evidence-based Practice Center Providence, RI Investigators: Issa J. Dahabreh, M.D., M.S. Dale W. Steele, M.D., M.S. Nishit Shah, M.D. Thomas A. Trikalinos, M.D., Ph.D. AHRQ Publication No. 14-EHC018-EF April 2014 This report is based on research conducted by the Brown University Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2012-00012-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients. This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. This report may periodically be assessed for the urgency to update. If an assessment is done, the resulting surveillance report describing the methodology and findings will be found on the Effective Health Care Program Web site at: www.effectivehealthcare.ahrq.gov. Search on the title of the report. This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated. Persons using assistive technology may not be able to fully access information in this report. For assistance contact [email protected]. None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report. Suggested citation: Dahabreh IJ, Steele DW, Shah N, Trikalinos TA. Oral Mechanical Bowel Preparation for Colorectal Surgery. Comparative Effectiveness Review No. 128. (Prepared by the Brown University Evidence-based Practice Center under Contract No. 290-2012-00012-I.) AHRQ Publication No. 14-EHC018-EF. Rockville, MD: Agency for Healthcare Research and Quality; April 2014. www.effectivehealthcare.ahrq.gov/reports/final.cfm. ii Preface The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of systematic reviews to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. These reviews provide comprehensive, science-based information on common, costly medical conditions, and new health care technologies and strategies. Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews can help clarify whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about AHRQ EPC systematic reviews, see www.effectivehealthcare.ahrq.gov/reference/purpose.cfm. AHRQ expects that these systematic reviews will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an email list to learn about new program products and opportunities for input. We welcome comments on this systematic review. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to [email protected]. Richard G. Kronick, Ph.D. Yen-pin Chiang, Ph.D. Director Acting Director, Center for Outcomes Agency for Healthcare Research and Quality and Evidence Agency for Healthcare Research and Quality Stephanie Chang, M.D., M.P.H. Director, EPC Program Elisabeth U. Kato, M.D., M.R.P. Center for Outcomes and Evidence Task Order Officer Agency for Healthcare Research and Quality Center for Outcomes and Evidence Agency for Healthcare Research and Quality iii Acknowledgments The authors would like to thank Dr. Cameron Platell (St. John of God Subiaco Hospital, Perth, Australia) for providing unpublished outcome data from a randomized trial included in this report; Dr. Mike Parker (Keyhole Surgery Ltd, Kent, United Kingdom) for providing clarifications regarding the mechanical preparation protocol for a randomized trial that was deemed ineligible for inclusion; and Dr. Shehzad Akbar Khan (Hayatabad Medical Complex, Peshawar, Pakistan) for providing access to study materials (reprints). The authors also acknowledge the individuals listed below for their contributions to this project: Key Informants In designing the study questions, the EPC consulted several Key Informants who represent the end-users of research. The EPC sought the Key Informant input on the priority areas for research and synthesis. Key Informants are not involved in the analysis of the evidence or the writing of the report. Therefore, in the end, study questions, design, methodological approaches, and/or conclusions do not necessarily represent the views of individual Key Informants. Key Informants must disclose any financial conflicts of interest greater than $10,000 and any other relevant business or professional conflicts of interest. Because of their role as end-users, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any conflicts of interest. The list of Key Informants who participated in developing this report follows: Fizan Abdullah, M.D., Ph.D. Robert Sawyer, M.D. Associate Professor of Surgery Professor of Surgery and Public Health Assistant Program Director, Residency in Sciences General Surgery Chief of Acute Care Surgery Associate Professor of International Health University of Virginia Health System Bloomberg School of Public Health Charlottesville, VA Program Director, Fellowship in Pediatric Surgery John Sperati, M.D. Johns Hopkins Children's Center Assistant Professor of Medicine Baltimore, MD Associate Program Director Osler Medical Residency Program Waleed Lutfiyya, M.D. Johns Hopkins Medical Institutions Kaiser Permanente Baltimore, MD Portland, OR Mark Welton, M.D. Laura Porter, M.D. Vice Chief of Staff, Stanford Hospital and Colon Cancer Alliance Clinics Washington, DC Professor of Surgery, Stanford University Medical School Stanford, CA iv Judy Zerzan, M.D., M.P.H. Chief Medical Officer/Deputy Medicaid Director Colorado Department of Health Care Policy and Financing Clinical Assistant Professor University of Colorado, Denver Denver, CO Technical Expert Panel In designing the study questions and methodology at the outset of this report, the EPC consulted several technical and content experts. Broad expertise and perspectives were sought. Divergent and conflicted opinions are common and perceived as healthy scientific discourse that results in a thoughtful, relevant systematic review. Therefore, in the end, study questions, design, methodologic approaches, and/or conclusions do not necessarily represent the views of individual technical and content experts. Technical Experts must disclose any financial conflicts of interest greater than $10,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential conflicts of interest identified. The list of Technical Experts who participated in developing this report follows: Michael Barza, M.D. Kamal Itani, M.D. Chief of Medicine and Program Director Professor of Surgery, Boston University Steward Carney Hospital Chief of General Surgery, Boston VA Vice Chairman for Clinical Affairs Health Care System Department of Medicine Boston, MA Tufts Medical Center Boston, MA Peter Mattei, M.D. Associate Professor of Surgery Nancy Baxter, M.D. University of Pennsylvania Associate Professor, Department of Surgery Attending Physician and Institute of Health Policy, Division of General, Thoracic and Fetal Management and Evaluation (IHPME) Surgery University of Toronto Children’s Hospital of Philadelphia Head, Division of General
Recommended publications
  • Hepatic Surgery
    Hepatic Surgery Honorary Editors: Tan To Cheung, Long R. Jiao Editors: Zhiming Wang, Giovanni Battista Levi Sandri, Alexander Parikh Associate Editors: Yiming Tao, Michael D. Kluger, Romaric Loffroy Editors: Zhiming Wang, Giovanni Battista Levi Sandri, Levi Battista Giovanni Alexander Parikh Hepatic Surgery Honorary Editors: Tan To Cheung, Long R. Jiao Editors: Zhiming Wang, Giovanni Battista Levi Sandri, Alexander Parikh Associate Editors: Yiming Tao, Michael D. Kluger, Romaric Loffroy AME Publishing Company Room C 16F, Kings Wing Plaza 1, NO. 3 on Kwan Street, Shatin, NT, Hong Kong Information on this title: www.amegroups.com For more information, contact [email protected] Copyright © AME Publishing Company. All rights reserved. This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of AME Publishing Company. First published in 2018 Printed in China by AME Publishing Company Editors: Zhiming Wang, Giovanni Battista Levi Sandri, Alexander Parikh Hepatic Surgery (Hard Cover) ISBN: 978-988-78919-1-8 AME Publishing Company, Hong Kong AME Publishing Company has no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate. The advice and opinions expressed in this book are solely those of the authors and do not necessarily represent the views or practices of the publisher. No representation is made by the publisher about the suitability of the information contained in this book, and there is no consent, endorsement or recommendation provided by the publisher, express or implied, with regard to its contents.
    [Show full text]
  • Belgian Veterinary Surveillance of Antibacterial Consumption
    Belgian Veterinary Surveillance of Antibacterial Consumption National consumption report 2013 1 Summary This fifth BelVetSAC report, covers the results of the data collection on veterinary antibacterial consumption in Belgium in the year 2013. Data consist of all veterinary antibacterials sold to a veterinarian or pharmacist in Belgium and of antibacterial premixes incorporated in medicated feed intended to be used in Belgium for the year 2013. It includes thus consumption data for farm animals as well as companion animals. The denominator for animal production was the biomass (in kg) calculated as the sum of the amount of beef, pork and poultry meat produced in 2013, plus the number of dairy cattle present in Belgium times 500 kg of metabolic weight per head. As the usage data are concerned, this report shows for the second year in a row a decrease in the total consumption of antibacterial compounds in veterinary medicine of -6,6% between 2012 and 2013. Due to the relative stable animal production (expressed in biomass -0,3%) the decrease expressed in mg/kg biomass is -6,3%. When using 2011 as a reference, a reduction of -12,7% (expressed in mg/kg biomass) was achieved between 2011 and 2013, distributed over a reduction of -13,3% in antibacterial pharmaceuticals and -10,2% in antibacterial premixes. When looking more in detail to the different types of antibacterials used, it is observed that the penicillines (31,1%), sulphonamides (28,7%), and tetracyclines (24,1%) remain the three most used antibacterial classes. This year a substantial decrease in sulphonamide plus trimethoprim use and a limited decrease in penicillin and tetracycline use was observed.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • DDSI Week 2019 Brochure
    DDSI WEEK 2019 Digestive Disease & Surgery Institute Week 30th Anniversary Jagelman 40th Anniversary Turnbull International Colorectal Disease Symposium February 14-16, 2019 Marriott Harbor Beach Resort & Spa Fort Lauderdale, Florida 3rd Annual Pelvic Dissection taTME Cadaver Lab February 13, 2019 | M.A.R.C., Coral Gables, Florida Get your CME and MOC Points (ABS & ABIM) Call for Abstracts Deadline: November 15, 2018 8th Annual Gastroenterology and Hepatology Symposium February 14-16, 2019 Marriott Harbor Beach Resort & Spa Fort Lauderdale, Florida REGISTER ONLINE AT www.ccfcme.org/DDSI-Week 30th Anniversary Jagelman / 40th Anniversary Turnbull International Colorectal Disease Symposium February 14-16, 2019 #ccfcrs19 3rd Annual Pelvic Dissection taTME Cadaver Lab #ddsiweek19 February 13, 2019 Please join us as we celebrate our 30th Anniversary Who Should Attend? David G. Jagelman MD / 40th Anniversary Rupert Physicians, residents, fellows, nurses, wound care B. Turnbull MD International Colorectal Disease professionals, physician assistants, and allied health Symposium as part of our annual Digestive Disease professionals specializing in colorectal surgery, general and Surgery Institute Week (DDSI). This internationally surgery, laparoscopic surgery, endoscopic surgery and acclaimed gathering of surgeons from around the world gastroenterology. will be held from February 14-16, 2019 at the newly remodeled Marriott Harbor Beach Resort & Spa in Fort Lauderdale. This special anniversary course is paying Sessions tribute to the more than 1,000 surgeons from the USA Wednesday, Feb 13 and virtually every other country who have trained 3rd Annual Pelvic Dissection taTME Cadaver Lab as clinicians and/or researchers at Cleveland Clinic, Location: M.A.R.C. (Miami Anatomical Research in Florida and/or in Ohio.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Colorectal Surgery Institute After You Complete Your Visit with Our Nurse, Dr
    Dear Patient, Your appointment with Dr. Garza will begin with our Nurse who will review your medical Robert W. Beart, M.D. history, pharmacy and medication information. Medical Director Colorectal Surgery Institute After you complete your visit with our nurse, Dr. Garza will discuss the nature of your Petar Vukasin, M.D. Colorectal Surgery problem with you. Dr. Garza may perform an examination, which may include an anoscopy or proctoscopic examination. AnaMaria Garza, M.D. Colorectal & General Surgery Jocelyn Moon, PA-C IMPORTANT – PLEASE BRING THE FOLLOWING ITEMS WITH YOU FOR YOUR APPOINTMENT: The enclosed Patient Questionnaire forms – please be sure to complete these before arriving for your appointment, including pharmacy and medications. All insurance cards, claim forms and drivers license. Pertinent operative reports, pathology reports, x‐ray films and their reports, diagnostic tests and their reports, and lab reports from your current physician. Should you have any questions, please feel free to contact me by phone at 818‐244‐8161, or e‐mail at [email protected] We look forward to meeting you and the opportunity to participate in your care. Sincerely, Colorectal Surgery Institute Attachments: Patient Medical History (Please complete) Patient Information (Please complete) Consent Form (Please complete) CSI‐GMH Patient Billing Information Conditions of Admission ‐ Glendale Memorial Hospital Maps and Directions – Glendale Memorial Hospital & Colorectal Surgery Institute 222 West Eulalia Street Dignity
    [Show full text]
  • Optimal Iron Replacement for Colorectal Cancer-Induced Anaemia Roderick J
    The Open Colorectal Cancer Journal, 2010, 3, 27-31 27 Open Access Optimal Iron Replacement for Colorectal Cancer-Induced Anaemia Roderick J. Alexander*, Alison Alexander, Sue Surgenor, Elizabeth J. Williams and Guy F. Nash Poole General Hospital, Longfleet Rd, Poole, Dorset BH15 2JB, UK Abstract: Introduction: Iron deficiency anaemia (IDA) is commonly a result of colorectal cancer. Higher preoperative haemoglobin (Hb) is associated with an improved post-operative survival. The endpoint of normalising patients Hb is to reduce the need for perioperative blood transfusion which has oncological, safety and economic benefits. Methods: This study aims to compare the overall effect and cost between oral iron and two forms of parenteral iron, in raising the Hb of 53 consecutive colorectal cancer patients with IDA. The pre- and post-treatment Hb were measuring over time for oral and two formulations of parenteral iron (CosmoFer® and Venofer®), as were the need for supplemental pre-operative blood transfusions. The Total Hb rise and Hb rise/day were calculated as was the overall cost (including blood transfusions) in each of the three iron supplementation groups. Results: Both total Hb rise and Hb rise/day were significantly higher in the Venofer® (p=0.048, p=0.002) and CosmoFer® groups (p=0.034 & p=0.001) over oral iron. The oral iron group required significantly more blood than the Venofer® (p=0.04) and CosmoFer® groups (p=0.01). Although there was a trend for oral iron to cost more than parenteral, this did not reach significance. Conclusions: This study suggests that the end point of transfusion reduction is possible by the increased Hb rise rate of Venofer® or CosmoFer®.
    [Show full text]
  • PHARMACEUTICAL STARTING MATERIALS List of Products
    PHARMACEUTICAL STARTING MATERIALS List of Products Acetylsalicylic Acid, Dextrose Anhydrous Ketamine Hydrochloride Povidone crystalline Acyclovir Diazepam Ketoconazole Pravastain Albendazole Diclofenac Potasium Ketoprofen Praziquantel Allopurinol Diclofenac Sodium Labetalol Prednisolone Aluminium Hydroxide Difloxacin Lamivudine Prednisolone Hydrochloride Acetate Amikacin Sulfate Dihydroartemisinin Levamisole Procaine Benzylpenicillin, sterile powder Aminophylline Dihydostreptomycin Levofloxacin Sterile Procaine Sulfate Powder Hydrochloride Amodiaquine Diloxanide Furoate Levonorgestrel Progesterone Hydrochloride Amoxicillin Trihydrate, Diphenhydramine Levothyroxine Sodium Promethazine non-sterile powder, Hydrochloride Hydrochloride compact Ampicillin Sodium, Doxazosin Mesylate Lidocaine Hydrochloride Propranolol sterile crystalline Hydrochloride Ampicillin Trihydrate, Doxycycline Hyclate Lincomycin Pyrantel Pamoate non-sterile powder Hydrochloride Ampicillin Trihydrate, Doxycycline Lisinopril Pyrazinamide compact powder Monohydrate Ascorbic Acid Econazole Nitrate L-Methionine Pyridoxine Hydrochloride, powder Atropine Sulfate Eflorinthine Loratadine Pyrimethamine Hydrochloride Azithromycin Enalapril Maleate Lovastatin Quinine Hydrochloride Benzanthine Enrofloxacin Magnesium Trisilicate Ramipril Benzylpenicillin, sterile Hydrochloride powder Benzylpenicillin Epinephrine Magnesium Sulfate, Ranitidine Potassium, sterile dried powder Hydrochloride powder Benzylpenicillin Ergocalciferol Mannitol Retinol Acetate Sodium, sterile powder Betamethasone
    [Show full text]
  • Design, Synthesis and Pharmacological Evaluation of Sulfanilamide-Ciprofloxacin Conjugates Utilizing Hybridization Approach As New Antibacterial Agents
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by International Institute for Science, Technology and Education (IISTE): E-Journals Journal of Natural Sciences Research www.iiste.org ISSN 2224-3186 (Paper) ISSN 2225-0921 (Online) Vol.5, No.4, 2015 Design, Synthesis and Pharmacological Evaluation of Sulfanilamide-Ciprofloxacin Conjugates Utilizing Hybridization Approach as New Antibacterial Agents Mohamed Hassan Mohammed 1 Monther Faisal Mahdi 2 Noor Hatef Naser 3 Sulaf Majeed Ali 4 1.Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Iraq 2.Department of Pharmaceutical Chemistry, College of Pharmacy, University of Al-Mustansiriyah, Baghdad, Iraq 3.Department of Pharmaceutical Chemistry, College of Pharmacy, University of Kufa,Najaf, Iraq 4.Ministry of Health, Directorate of General Health National Reference Laboratory E-Mail of Corresponding author :[email protected] Abstract A group of novel antibacterial agents (I-V) were designed and synthesized, by utilizing hybridization approach between ciprofloxacin and sulfanilamide, through metabolically stable linkers, to be acted by dual mode of actions. Ciprofloxacin acts by inhibition of topoisomerase enzyme, which is necessary for DNA replication, while sulfonamides act through inhibition of carbonic anhydrase enzyme, which is necessary for bacterial metabolic activity. Anti-tuberculosis activity of these compounds was evaluated on MDR Mycobacterium tuberculosis (resist to rifampicin and INH), in a dose equivalent to (10 mg/ 5 ml D.W.) of ciprofloxacin. Compounds II, III showed non-significant reduction in the number of bacterial colonies (bacterial growth) with respect to the effect of ciprofloxacin (standard), compound IV produce a significant reduction in the number of bacterial colonies in comparable to ciprofloxacin.
    [Show full text]
  • Preparing for Your Colorectal Surgery Important Contact Information
    Preparing For Your Colorectal Surgery Important Contact Information Your surgeon’s name: __________________________________________________________________ Your surgeon’s phone number: (______) ___________________________________________________ Your colorectal nurse navigator’s name: ________________________________________________ Your colorectal nurse navigator’s phone number: (______) _______________________________ Welcome to Tampa General Hospital Tampa General Hospital Pre-admission Testing Center phone number: (______) ___________________________________ Welcome to Tampa General Hospital (TGH). We are committed to your comfort and safety and want to do everything we can to make your stay as pleasant as possible. The information in this booklet will help you prepare for your surgery and recovery. We encourage you to read it and if you have any questions, ask the doctors and nurses caring for you. If you have family members, caregivers or friends caring for you, please have them read this book and also Dates to Remember encourage them to ask questions about anything that may be of concern. Date and time of Pre-admission Testing Center appointment: ____________________________ Date and arrival time for surgery: _______________________________________________________ Date and time of post surgery clinic visit: ________________________________________________ Other Appointments (as applicable) Ostomy Clinic date and time: ____________________________________________________ Primary care physician date and time: ___________________________________________
    [Show full text]
  • Sulfonamides and Sulfonamide Combinations*
    Sulfonamides and Sulfonamide Combinations* Overview Due to low cost and relative efficacy against many common bacterial infections, sulfonamides and sulfonamide combinations with diaminopyrimidines are some of the most common antibacterial agents utilized in veterinary medicine. The sulfonamides are derived from sulfanilamide. These chemicals are structural analogues of ρ-aminobenzoic acid (PABA). All sulfonamides are characterized by the same chemical nucleus. Functional groups are added to the amino group or substitutions made on the amino group to facilitate varying chemical, physical and pharmacologic properties and antibacterial spectra. Most sulfonamides are too alkaline for routine parenteral use. Therefore the drug is most commonly administered orally except in life threatening systemic infections. However, sulfonamide preparations can be administered orally, intramuscularly, intravenously, intraperitoneally, intrauterally and topically. Sulfonamides are effective against Gram-positive and Gram-negative bacteria. Some protozoa, such as coccidians, Toxoplasma species and plasmodia, are generally sensitive. Chlamydia, Nocardia and Actinomyces species are also sensitive. Veterinary diseases commonly treated by sulfonamides are actinobacillosis, coccidioidosis, mastitis, metritis, colibacillosis, pododermatitis, polyarthritis, respiratory infections and toxo- plasmosis. Strains of rickettsiae, Pseudomonas, Klebsiella, Proteus, Clostridium and Leptospira species are often highly resistant. Sulfonamides are bacteriostatic antimicrobials
    [Show full text]